title: The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.
abstract: Dysregulated tyrosine kinase activity by the Fip1-like1 (FIP1L1)-platelet-derived growth factor receptor alpha (PDGFRA) (F/P) fusion gene has been identified as a cause of clonal hypereosinophilic syndrome (HES), called F/P-positive chronic eosinophilic leukemia (CEL) in humans. However, transplantation of F/P-transduced hematopoietic stem cells/progenitors (F/P(+) HSCs/Ps) into mice results in a chronic myelogenous leukemia-like disease, which does not resemble HES. Because a subgroup of patients with HES show T-cell-dependent interleukin-5 (IL-5) overexpression, we determined if expression of the F/P fusion gene in the presence of transgenic T-cell IL-5 overexpression in mice induces HES-like disease. Mice that received a transplant of CD2-IL-5-transgenic F/P(+) HSC/Ps (IL-5Tg-F/P) developed intense leukocytosis, strikingly high eosinophilia, and eosinophilic infiltration of nonhematopoietic as well as hematopoietic tissues, a phenotype resembling human HES. The disease phenotype was transferable to secondary transplant recipients of a high cell dose, suggesting involvement of a short-term repopulating stem cell or an early myeloid progenitor. Induction of significant eosinophilia was specific for F/P since expression of another fusion oncogene, p210-BCR/ABL, in the presence of IL-5 overexpression was characterized by a significantly lower eosinophilia than IL-5Tg-F/P recipients. These results suggest that F/P is not sufficient to induce a HES/CEL-like disease but requires a second event associated with IL-5 overexpression.
authors.affiliation: Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Yamada
authors.forename: Marc E
authors.initials: ME
authors.lastname: Rothenberg
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Lee
authors.forename: Hiroko Saito
authors.initials: HS
authors.lastname: Akei
authors.forename: Eric B
authors.initials: EB
authors.lastname: Brandt
authors.forename: David A
authors.initials: DA
authors.lastname: Williams
authors.forename: Jose A
authors.initials: JA
authors.lastname: Cancelas
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D004195:Disease Models, Animal; D004804:Eosinophils / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D017681:Hypereosinophilic Syndrome / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D015848:Interleukin-5 / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D013154:Spleen / Q000473:pathology; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
chemical_list: D015848:Interleukin-5; D015514:Oncogene Proteins, Fusion; D039221:mRNA Cleavage and Polyadenylation Factors; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha